论文部分内容阅读
由日本Taiho Oncology Inc.生产的复方口服药物Lonsurf于2015年9月22日获得美国食品药品监督管理局(FDA)批准在美国上市。Lonsurf是由三氟胸苷(trifluridine,FTD)和地匹福林盐酸盐(tipiracil hydrochloride,TPI)组成的复方制剂,用于对其他疗法(化疗及生物疗法)不再响应的转移性结直肠癌(m CRC)的治疗~([1])。三氟胸苷的中文化学名称:α,α,α-三氟胸苷;英文化
Lonsurf, a compound oral drug manufactured by Japan’s Taiho Oncology Inc., was approved by the U.S. Food and Drug Administration (FDA) for listing in the United States on September 22, Lonsurf is a combination of trifluridine (FTD) and tipiracil hydrochloride (TPI) for use in metastatic colorectal cancers that no longer respond to other therapies (chemotherapy and biotherapy) Cancer (m CRC) treatment ~ ([1]). Trifluorothymidine Chinese chemical name: α, α, α-trifluorothymidine; English